Group 1 - Day One Biopharmaceuticals (NASDAQ:DAWN) has agreed to acquire Mersana Therapeutics Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs) targeting cancers [1][2] - The acquisition deal includes an upfront payment of $25.00 per share in cash, with potential additional payments under contingent value rights, leading to a total equity value of approximately $129 million and a total deal value of up to roughly $285 million [2] - Day One is focused on pediatric cancers and has a pipeline that includes tovorafenib (Ojemda) and DAY301 [2] Group 2 - In Q3, Ojemda's net product revenue reached $38.5 million, up from $20.1 million year-over-year, driven by increased patient demand [3] - The company has raised its full-year 2025 net product revenue guidance for Ojemda to between $145 million and $150 million, indicating continued strength in demand [3] - Quarterly prescriptions for Ojemda grew to 1,256 in Q3 2025, representing an 18% increase compared to Q2 2025 [3] Group 3 - Day One ended Q3 with $451.6 million in cash, cash equivalents, and short-term investments [4] - The acquisition of Mersana provides an opportunity to support the development of Emi-Le for patients with adenoid cystic carcinoma, addressing a high unmet need [4] - The Mersana board has unanimously approved the transaction, with closing expected by the end of January 2026 [5] Group 4 - Mersana Therapeutics shares increased by 206.82% to $27.21, while Day One Biopharmaceutical shares decreased by 5.78% to $9.74 at the time of publication [5]